Literature DB >> 6883274

Atrophic chronic gastritis and intestinal metaplasia in gastric carcinoma. Comparison with a representative population sample.

P Sipponen, M Kekki, M Siurala.   

Abstract

The occurrence of chronic gastritis and intestinal metaplasia (IM) was studied in 257 patients with gastric carcinoma (GC). In all cases biopsies were available from the benign mucosal area adjacent to the tumor, and in 139 patients from the antrum and/or body mucosa outside the tumor. The results were compared with endoscopically and bioptically examined noncancer controls representing a large Finnish population sample. For every GC patient, a control subject was matched by age and sex. In addition, a mean age-adjusted score (AAS) of chronic gastritis, which expresses the progression of gastritis in GC patients as compared with that in the general population, was calculated for GC patients. The prevalences of chronic and atrophic gastritis in the antrum and body mucosa were similar in GC patients and controls when carcinoma cases were not more specifically classified according to histologic type or location of tumors. On the other hand, the location of the tumor showed a significant relation to gastritis: the progression of gastritis was more rapid (high mean AAS value) and the prevalence of atrophic gastritis was higher in the tumor-affected area (i.e., in the antrum in patients with antral [distal] tumors; in the body in patients with body [proximal] tumors), than in the general population, but were similar in the tumor-free area in both GC patients and controls. In the intestinal type of GC (IGC), the prevalence of chronic gastritis was higher and its progression was more rapid than in controls. In the diffuse type of GC (DGC), these correlations were less distinct. In GC patients, the IM adjacent to and outside the tumor area was significantly more common and extensive than in the corresponding area of controls, and a significant positive correlation was present between the location of the tumor and the distribution of IM. Like gastritis, the IM showed a closer relationship to IGC than to DGC. In all cases of GC and particularly of IGC, the antral mucosa tended to be more severely affected by gastritis and IM than the body mucosa, i.e., the prevailing type of gastritis found in this GC series was that morphologically corresponding to the so-called B-type of chronic gastritis.

Entities:  

Mesh:

Year:  1983        PMID: 6883274     DOI: 10.1002/1097-0142(19830915)52:6<1062::aid-cncr2820520622>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  28 in total

1.  Comparison of precancerous conditions: atrophy and intestinal metaplasia in Helicobacter pylori gastritis among Chinese and Dutch patients.

Authors:  X Y Chen; R W van Der Hulst; Y Shi; S D Xiao; G N Tytgat; F J Ten Kate
Journal:  J Clin Pathol       Date:  2001-05       Impact factor: 3.411

Review 2.  Update on the Diagnosis and Management of Gastric Intestinal Metaplasia in the USA.

Authors:  Judy A Trieu; Mohammad Bilal; Hamzeh Saraireh; Andrew Y Wang
Journal:  Dig Dis Sci       Date:  2019-05       Impact factor: 3.199

3.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Virchows Arch       Date:  2011-12-22       Impact factor: 4.064

4.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Endoscopy       Date:  2011-12-23       Impact factor: 10.093

5.  General features of gastric carcinomas and comparison of HSP70 and NK cell immunoreactivity with prognostic factors.

Authors:  Ozlem Canöz; Olcay Belenli; Tahír E Patiroglu
Journal:  Pathol Oncol Res       Date:  2003-02-11       Impact factor: 3.201

6.  Cytokine gene expression in the gastric mucosa: its role in chronic gastritis.

Authors:  S Ishihara; R Fukuda; S Fukumoto
Journal:  J Gastroenterol       Date:  1996-08       Impact factor: 7.527

7.  Incomplete sulphomucin-secreting intestinal metaplasia for gastric cancer. Preliminary data from a prospective study from three centres.

Authors:  M I Filipe; F Potet; W V Bogomoletz; P A Dawson; B Fabiani; P Chauveinc; A Fenzy; B Gazzard; D Goldfain; R Zeegen
Journal:  Gut       Date:  1985-12       Impact factor: 23.059

8.  Importance of different CD44v6 expression in human gastric intestinal and diffuse type cancers for metastatic lymphogenic spreading.

Authors:  J Dämmrich; H P Vollmers; K H Heider; H K Müller-Hermelink
Journal:  J Mol Med (Berl)       Date:  1995-08       Impact factor: 4.599

9.  Diffuse and intestinal type gastric carcinomas differ in their expression of apoptosis related proteins.

Authors:  C J van der Woude; J H Kleibeuker; A T G M Tiebosch; M Homan; A Beuving; P L M Jansen; H Moshage
Journal:  J Clin Pathol       Date:  2003-09       Impact factor: 3.411

Review 10.  Pathophysiological effects of long-term acid suppression in man.

Authors:  R F McCloy; R Arnold; K D Bardhan; D Cattan; E Klinkenberg-Knol; P N Maton; R H Riddell; P Sipponen; A Walan
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.